Designs and manufactures containment systems for injectable drugs. Provides delivery systems for healthcare products. Now — the numbers.
That much dependence is a risk in itself: if this one line weakens, the whole company feels it directly.
This is an established company with proven profits.
We compared this company with its own sector across five subjects.
A score of 50 means class average.
Profit power and business quality lead the class.
Debt is low and cash is strong; the finances stand solid.
Clearly below the class average.
This grade is a blend: the profit side is strong, the sales tempo slow.
Clearly above the class average — a step short of the very top.
Valuation: The stock trades at a price that looks expensive next to its earnings; that can cap future returns.
The stock trades 27% below its peak. The market has trimmed its expectations for the company.
The net profit margin is 16% — still a thick cushion, though costs have been eating into it lately.
There is $791.3M in the vault; even if every debt were paid off, $374.6M would remain.
It met or beat analyst expectations in 8 of the last 8 quarters — consistency is a promise kept.
Over the last 4 years, sales grew only 2% a year on average — the report card’s higher growth grade leans on profit power instead.
The company’s market value is 49 times its annual profit. Even a small disappointment could hit the price hard.
On our five-subject report card, WST sits near the top of the class. A high grade doesn’t mean “guaranteed win” — it means “the evidence looks strong for now.”
The takeaway: WST is an established business that has proven its profits for years. The real debate isn’t the quality of the business — it’s whether the price paid for the stock is too high.
The total grade weighs these five subjects against the sector — it isn’t a simple average of the five.
Analysts’ average target sits above today’s price, yet the valuation grade (41/100) says the stock isn’t cheap.